Hybrid multiepitope recombinant vaccine for protection against infection caused by group B streptococcus

Abstract

BACKGROUND: Streptococcus agalactiae, commonly known as group B streptococcus, is an important pathogen responsible for severe and sometimes fatal invasive infections in newborns. It also poses a significant risk to older adults and those with weakened immune systems. Current preventive strategies primarily include the use of antibiotics to prevent maternal-to-fetal transmission of group B streptococcus and to treat established infections. The emergence of antibiotic-resistant strains has reduced the effectiveness of these treatments and highlighted the need for alternative preventive measures. Vaccines represent a promising complement to antibiotics, potentially providing broader and more effective protection against group B streptococcus infections.

AIM: The study aims to evaluate the immunogenic properties and protective efficacy of a newly developed chimeric recombinant protein vaccine (Su4) designed to combat group B streptococcus infections. This vaccine incorporates immunodominant epitopes from five group B streptococcus virulence factor proteins. The research investigated various vaccination methods in mice, followed by an analysis of the effectiveness of the induced immune response in providing protection against multiple forms of group B streptococcus infection.

MATERIALS AND METHODS: Female outbred mice (6–8 weeks of age) were immunized subcutaneously, intranasally, or intravaginally with a hybrid recombinant vaccine polypeptide Su4 at a dose of 20 μg with repeated administration at the same dose after 21 days. Blood samples were taken from the submandibular vein on days 20 and 40 after immunization. Immunogenicity was assessed by measuring the levels of specific IgG, IgG1, IgG2a and IgG3 using ELISA. The plates were coated with Su4 protein or recombinant peptide analogs of each of the five regions of the Su4 complex molecule, and antibody concentrations were determined using standard curves. Protective efficacy was assessed by the bacterial load in the lungs and vaginal lavages of mice infected with the group B streptococcus strain 6224 nasally or vaginally at a dose of 10⁸ CFU/mouse. Bacterial concentrations in lung homogenates and vaginal washings were determined by plating the material on Columbia blood agar.

RESULTS: The study examined the protective effectiveness of vaccination with the polyepitope molecule Su4, consisting of linear determinants of five group B streptococcus proteins. Immunization by subcutaneous, intranasal and vaginal routes showed that the Su4 protein was immunogenic and caused the production of specific IgG. Subcutaneous immunization ensured the accumulation of the highest levels of antibodies. The immune response developed according to the Th2 type and predominantly led to the induction of IgG1 antibodies, potentially capable of opsonizing bacteria and initiating phagocytosis. Vaccination resulted in accelerated clearance of group B streptococcus from the vaginal cavity of mice following infection compared with the control group, demonstrating the protective effectiveness of the stimulated immune response in protecting against group B streptococcus infections.

CONCLUSIONS: The polyepitope chimeric recombinant protein Su4 is immunogenic via subcutaneous, intranasal, and vaginal administration, inducing a systemic IgG response specific to group B streptococcus proteins. This response enhances resistance to nasal and vaginal group B streptococcus infections, indicating that Su4 is a promising candidate for a multi-epitope vaccine against group B streptococcus.

Keywords

group B streptococcus / hybrid recombinant vaccine / protective efficacy / mucosal vaccination

References

[1] Spellerberg B. Pathogenesis of neonatal Streptococcus agalactiae infections. Microbes Infect. 2000;2(14):1733–1742. doi: 10.1016/s1286-4579(00)01328-9

[2] Spellerberg B. Pathogenesis of neonatal Streptococcus agalactiae infections // Microbes Infect. 2000. Vol. 2, N 14. P. 1733–1742 . doi: 10.1016/s1286-4579(00)01328-9

[3] Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis. 2005;41(6):839–847. doi: 10.1086/432804

[4] Edwards M.S., Baker C.J. Group B streptococcal infections in elderly adults // Clin Infect Dis. 2005. Vol. 41, N 6. P. 839–847. doi: 10.1086/432804

[5] Sambola A, Miro JM, Tornos MP, et al. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962–1998. Clin Infect Dis. 2002;34(12):1576–1584. doi: 10.1086/340538

[6] Sambola A., Miro J.M., Tornos M.P., et al. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962–1998 // Clin Infect Dis. 2002. Vol. 34, N 12. P. 1576–1584. doi: 10.1086/340538

[7] Rollán MJ, San Román JA, Vilacosta I, et al. Clinical profile of Streptococcus agalactiae native valve endocarditis. Am Heart J. 2003;146(6):1095–1098. doi: 10.1016/S0002-8703(03)00444-7

[8] Rollán M.J., San Román J.A., Vilacosta I., et al. Clinical profile of Streptococcus agalactiae native valve endocarditis // Am Heart J. 2003. Vol. 146, N 6. P. 1095–1098. doi: 10.1016/S0002-8703(03)00444-7

[9] Scully BE, Spriggs D, Neu HC. Streptococcus agalactiae (group B) endocarditis – a description of twelve cases and review of the literature. Infection. 1987;15(3):169–176. doi: 10.1007/BF01646041

[10] Scully B.E., Spriggs D., Neu H.C. Streptococcus agalactiae (group B) endocarditis – a description of twelve cases and review of the literature // Infection. 1987. Vol. 15, N 3. P. 169–176. doi: 10.1007/BF01646041

[11] Le Doare K, Heath PT. An overview of global GBS epidemiology. Vaccine. 2013;31 Suppl 4:D7–12. doi: 10.1016/j.vaccine.2013.01.009

[12] Le Doare K., Heath P.T. An overview of global GBS epidemiology // Vaccine. 2013. Vol. 31 Suppl 4. P. D7–12. doi: 10.1016/j.vaccine.2013.01.009

[13] Gizachew M, Tiruneh M, Moges F, Tessema B. Streptococcus agalactiae maternal colonization, antibiotic resistance and serotype profiles in Africa: a meta-analysis. Ann Clin Microbiol Antimicrob. 2019;18(1):14. doi: 10.1186/s12941-019-0313-1

[14] Gizachew M., Tiruneh M., Moges F., Tessema B. Streptococcus agalactiae maternal colonization, antibiotic resistance and serotype profiles in Africa: a meta-analysis // Ann Clin Microbiol Antimicrob. 2019. Vol. 18, N 1. P. 14. doi: 10.1186/s12941-019-0313-1

[15] Wang P, Tong JJ, Ma XH, et al. Serotypes, antibiotic susceptibilities, and multi-locus sequence type profiles of Streptococcus agalactiae isolates circulating in Beijing, China. PLoS One. 2015;10(3):e0120035. doi: 10.1371/journal.pone.012003

[16] Wang P., Tong J.J., Ma X.H., et al. Serotypes, antibiotic susceptibilities, and multi-locus sequence type profiles of Streptococcus agalactiae isolates circulating in Beijing, China // PLoS One. 2015. Vol. 10, N 3. P. e0120035. doi: 10.1371/journal.pone.012003

[17] Cheng Z, Qu P, Ke P, et al. Antibiotic resistance and molecular epidemiological characteristics of Streptococcus agalactiae isolated from pregnant women in Guangzhou, South China. Can J Infect Dis Med Microbiol . 2020;2020:1368942. doi: 10.1155/2020/13689425

[18] Cheng Z., Qu P., Ke P., et al. Antibiotic resistance and molecular epidemiological characteristics of Streptococcus agalactiae isolated from pregnant women in Guangzhou, South China // Can J Infect Dis Med Microbiol. 2020. Vol. 2020. P. 1368942. doi: 10.1155/2020/13689425

[19] Carreras-Abad C, Ramkhelawon L, Heath PT, Le Doare K. A vaccine against group B streptococcus: recent advances. Infect Drug Resist. 2020;13:1263–1272. doi: 10.2147/IDR.S203454

[20] Carreras-Abad C., Ramkhelawon L., Heath P.T., Le Doare K. A vaccine against group B streptococcus: recent advances // Infect Drug Resist. 2020. Vol. 13. P. 1263–1272. doi: 10.2147/IDR.S203454

[21] Kim S-Y, Nguyen C, Russell LB, et al. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States. Vaccine. 2017;35(45):6238–6247. doi: 10.1016/j.vaccine.2017.08.085

[22] Kim S.-Y., Nguyen C., Russell L.B., et al. Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States // Vaccine. 2017. Vol. 35, N 45. P. 6238–6247. doi: 10.1016/j.vaccine.2017.08.085

[23] Kim SY, Russell LB, Park J, et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine. 2014;32(17):1954–1963. doi: 10.1016/j.vaccine.2014.01.062

[24] Kim S.Y., Russell L.B., Park J., et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa // Vaccine. 2014. Vol. 32, N 17. P. 1954–1963. doi: 10.1016/j.vaccine.2014.01.062

[25] Hartley J, Li Y, Kunkel L, Crowcroft NS. The burden of infant group B streptococcal infections in Ontario: Analysis of administrative data to estimate the potential benefits of new vaccines. Hum Vaccin Immunother. 2019;15(1):193–202. doi: 10.1080/21645515.2018.1511666

[26] Hartley J., Li Y., Kunkel L., Crowcroft N.S. The burden of infant group B streptococcal infections in Ontario: Analysis of administrative data to estimate the potential benefits of new vaccines // Hum Vaccin Immunother. 2019. Vol. 15, N 1. P. 193–202. doi: 10.1080/21645515.2018.1511666

[27] Baker CJ, Rench MA, Edwards MS, et al. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med. 1988;319(18):1180–1185. doi: 10.1056/NEJM198811033191802

[28] Baker C.J., Rench M.A., Edwards M.S., et al. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus // N Engl J Med. 1988. Vol. 319, N 18. P. 1180–1185. doi: 10.1056/NEJM198811033191802

[29] Baker CJ, Rench MA, Fernandez M, et al. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis. 2003;188(1):66–73. doi: 10.1086/375536

[30] Baker C.J., Rench M.A., Fernandez M., et al. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III // J Infect Dis. 2003. Vol. 188, N 1. P. 66–73. doi: 10.1086/375536

[31] Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003;21(24):3468–3472 . doi: 10.1016/s0264-410x(03)00353-0

[32] Baker C.J., Rench M.A., McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine // Vaccine. 2003. Vol. 21, N 24. P. 3468–3472. doi: 10.1016/s0264-410x(03)00353-0

[33] Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types IA and IB . J Infect Dis . 1999;179(1):142–150. doi: 10.1086/314574

[34] Baker C.J., Paoletti L.C., Wessels M.R., et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types IA and IB // J Infect Dis. 1999. Vol. 179, N 1. P. 142–150. doi: 10.1086/314574

[35] Baker CJ, Paoletti LC, Rench MA, et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis. 2004;189(6):1103–1112. doi: 10.1086/382193

[36] Baker C.J., Paoletti L.C., Rench M.A., et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines // J Infect Dis. 2004. Vol. 189, N 6. P. 1103–1112. doi: 10.1086/382193

[37] Heath PT. An update on vaccination against group B streptococcus. Expert Rev Vaccines. 2011;10(5):685–694. doi: 10.1586/erv.11.61

[38] Heath P.T. An update on vaccination against group B streptococcus // Expert Rev Vaccines. 2011. Vol. 10, N 5. P. 685–694. doi: 10.1586/erv.11.61

[39] Larsson C, Stålhammar-Carlemalm M, Lindahl G. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. Vaccine. 1999;17(5):454–458. doi: 10.1016/s0264-410x(98)00218-7

[40] Larsson C., Stålhammar-Carlemalm M., Lindahl G. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine // Vaccine. 1999. Vol. 17, N 5. P. 454–458. doi: 10.1016/s0264-410x(98)00218-7

[41] Madhi SA, Anderson AS, Absalon J, et al. Potential for maternally administered vaccine for infant group B streptococcus. N Engl J Med. 2023;389(3):215–227. doi: 10.1056/NEJMoa2116045

[42] Madhi S.A., Anderson A.S., Absalon J., et al. Potential for maternally administered vaccine for infant group B streptococcus // N Engl J Med. 2023. Vol. 389, N 3. P. 215–227. doi: 10.1056/NEJMoa2116045

[43] Fischer P, Pawlowski A, Cao D, et al. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women. Vaccine. 2021;39(32):4489–4499. doi: 10.1016/j.vaccine.2021.06.046

[44] Fischer P., Pawlowski A., Cao D., et al. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women // Vaccine. 2021. Vol. 39, N 32. P. 4489–4499. doi: 10.1016/j.vaccine.2021.06.046

[45] Gavi.org [Internet]. Available from: https://www.gavi.org/vaccineswork/routine-vaccines-extraordinary-impact-group-b-streptococcus-gbs . Accessed: 2024 Dec 25.

[46] Gavi.org [Электронный ресурс]. Режим доступа: https://www.gavi.org/vaccineswork/routine-vaccines-extraordinary-impact-group-b-streptococcus-gbs . Дата обращения: 25.12.2024.

[47] Larsson C, Lindroth M, Nordin P, et al. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed . 2006;91(6):F403–408. doi: 10.1136/adc.2005.090472

[48] Larsson C., Lindroth M., Nordin P., et al. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection // Arch Dis Child Fetal Neonatal Ed. 2006. Vol. 91, N 6. P. F403–408. doi: 10.1136/adc.2005.090472

[49] Santi I, Maione D, Galeotti CL, et al. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus . J Infect Dis. 2009;200(4):564–570. doi: 10.1086/603540

[50] Santi I., Maione D., Galeotti C.L., et al. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus // J Infect Dis. 2009. Vol. 200, N 4. P. 564–570. doi: 10.1086/603540

[51] Brodeur BR, Boyer M, Charlebois I, et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect Immun. 2000;68(10):5610–5618. doi: 10.1128/IAI.68.10.5610-5618.2000

[52] Brodeur B.R., Boyer M., Charlebois I., et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity // Infect Immun. 2000. Vol. 68, N 10. P. 5610–5618. doi: 10.1128/IAI.68.10.5610-5618.2000

[53] Kramskaya TA, Leontyeva GF, Grabovskaya KB, et al. Study of the protective mechanisms of action of a polyvalent recombinant vaccine based on conservative proteins for the prevention of infections caused by group B streptococci. Medical alphabet. 2015;1(6):30–33. (In Russ.) EDN: UCMAUP

[54] Крамская Т.А., Леонтьева Г.Ф., Грабовская К.Б., и др. Исследование защитных механизмов действия препарата поливалентной рекомбинантной вакцины на основе консервативных белков для профилактики инфекций, вызываемых стрептококками группы В // Медицинский алфавит. 2015. Т. 1, № 6. С. 30–33. EDN: UCMAUP

[55] Felgner S, Spöring I, Pawar V, et al. The immunogenic potential of bacterial flagella for Salmonella -mediated tumor therapy. Int J Cancer. 2020;147(2):448–460. doi: 10.1002/ijc.32807

[56] Felgner S., Spöring I., Pawar V., et al. The immunogenic potential of bacterial flagella for Salmonella -mediated tumor therapy // Int J Cancer. 2020. Vol. 147, N 2. P. 448–460. doi: 10.1002/ijc.32807

[57] Filimonova VYu, Dukhovlinov IV, Kramskaya TA, et al. Chimeric proteins based on immunogenic epitopes of surface pathogenicity factors of streptococci as a vaccine for the prevention of infection caused by group B streptococci. Medical Academic Journal. 2016;16(3):82–90. EDN: XDNAAZ

[58] Филимонова В.Ю., Духовлинов И.В., Крамская Т.А., и др. Химерные белки на основе иммуногенных эпитопов поверхностных факторов патогенности стрептококков в качестве вакцины для профилактики инфекции, вызванной стрептококками группы В // Медицинский академический журнал. 2016. Т. 16, № 3. С. 82–90. EDN: XDNAAZ

[59] Suvorov A, Dukhovlinov I, Leontieva G, et al. Chimeric Protein PSPF, a potential vaccine for prevention streptococcus pneumonia infection. Vaccines and Vaccination. 2015;2015(6):1–8. doi: 10.4172/2157-7560.10000304

[60] Suvorov A., Dukhovlinov I., Leontieva G., et al. Chimeric Protein PSPF, a potential vaccine for prevention streptococcus pneumonia infection // Vaccines and Vaccination. 2015. Vol. 2015, N 6. P. 1–8. doi: 10.4172/2157-7560.10000304

[61] Majumder K. Ligation-free gene synthesis by PCR: synthesis and mutagenesis at multiple loci of a chimeric gene encoding OmpA signal peptide and hirudin. Gene. 1992;110(1):89–94. doi: 10.1016/0378-1119(92)90448-x Erratum in: Gene. 1992;116(1):115–116. doi: 10.1016/0378-1119(92)90638-6 Erratum in: Gene. 1992;122(2):389.

[62] Majumder K. Ligation-free gene synthesis by PCR: synthesis and mutagenesis at multiple loci of a chimeric gene encoding OmpA signal peptide and hirudin // Gene. 1992. Vol. 110, N 1. P. 89–94. doi: 10.1016/0378-1119(92)90448-x Erratum in: Gene. 1992. Vol. 116, N 1. P. 115–116. doi: 10.1016/0378-1119(92)90638-6 Erratum in: Gene. 1992. Vol. 122, N 2. P. 389.

[63] Dzanibe S, Kwatra G, Adrian PV, et al. Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy. Sci Rep. 2017;7(1):16454. doi: 10.1038/s41598-017-16757-9

[64] Dzanibe S., Kwatra G., Adrian P.V., et al. Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy // Sci Rep. 2017. Vol. 7, N 1. P. 16454. doi: 10.1038/s41598-017-16757-9

[65] Procter SR, Gonçalves BP, Paul P, et al. Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness. PLoS Med. 2023;20(3):e1004068. doi: 10.1371/journal.pmed.1004068

[66] Procter S.R., Gonçalves B.P., Paul P., et al. Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness // PLoS Med. 2023. Vol. 20, N 3. P. e1004068. doi: 10.1371/journal.pmed.1004068

[67] Gupalova T, Leontieva G, Kramskaya T, et al. Development of experimental GBS vaccine for mucosal immunization. PloS One. 2018;13(5):e0196564. doi: 10.1371/journal.pone.0196564

[68] Gupalova T., Leontieva G., Kramskaya T., et al. Development of experimental GBS vaccine for mucosal immunization // PloS One. 2018. Vol. 13, N 5. P. e0196564. doi: 10.1371/journal.pone.0196564

[69] Furfaro LL, Chang BJ, Payne MS. Perinatal Streptococcus agalactiae epidemiology and surveillance targets. Clin Microbiol Rev. 2018;31(4):e00049–18. doi: 10.1128/CMR.00049-18

[70] Furfaro L.L., Chang B.J., Payne M.S. Perinatal Streptococcus agalactiae epidemiology and surveillance targets // Clin Microbiol Rev. 2018. Vol. 31, N 4. P. e00049–18. doi: 10.1128/CMR.00049-18

[71] Bambini S, Rappuoli R. The use of genomics in microbial vaccine development. Drug Discov Today . 2009;14(5–6):252–260. doi: 10.1016/j.drudis.2008.12.007

[72] Bambini S., Rappuoli R. The use of genomics in microbial vaccine development // Drug Discov Today. 2009. Vol. 14, N 5–6. P. 252–260. doi: 10.1016/j.drudis.2008.12.007

[73] Suvorov A, Ustinovitch I, Meringova L, et al. Construction of recombinant polypeptides based on beta antigen C (Bac) protein & their usage for protection against group B streptococcal infection. Indian J Med Res. 2004;119 Suppl:228–232.

[74] Suvorov A., Ustinovitch I., Meringova L., et al. Construction of recombinant polypeptides based on beta antigen C (Bac) protein and their usage for protection against group B streptococcal infection // Indian J Med Res. 2004. Vol. 119 Suppl. P. 228–232.

[75] Vorobieva EI, Meringova LF, Leontieva GF, et al. Analysis of recombinant group B streptococcal protein ScaAB and evaluation of its immunogenicity. Folia Microbiol (Praha). 2005;50(2):172–176 . doi: 10.1007/BF02931468

[76] Vorobieva E.I., Meringova L.F., Leontieva G.F., et al. Analysis of recombinant group B streptococcal protein ScaAB and evaluation of its immunogenicity // Folia Microbiol (Praha). 2005. Vol. 50, N 2. P. 172–176. doi: 10.1007/BF02931468

[77] Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000;342(1):15–20. doi: 10.1056/NEJM200001063420103

[78] Schrag S.J., Zywicki S., Farley M.M., et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis // N Engl J Med. 2000. Vol. 342, N 1. P. 15–20. doi: 10.1056/NEJM200001063420103

[79] Michel JL, Madoff LC, Kling DE, et al. Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun. 1991;59(6):2023–2028. doi: 10.1128/iai.59.6.2023-2028.1991

[80] Michel J.L., Madoff L.C., Kling D.E., et al. Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity // Infect Immun. 1991. Vol. 59, N 6. P. 2023–2028. doi: 10.1128/iai.59.6.2023-2028.1991

[81] Navarre WW, Schneewind O. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev. 1999;63(1):174–229. doi: 10.1128/MMBR.63.1.174-229.1999

[82] Navarre W.W., Schneewind O. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope // Microbiol Mol Biol Rev. 1999. Vol. 63, N 1. P. 174–229. doi: 10.1128/MMBR.63.1.174-229.1999

[83] Santillan DA, Rai KK, Santillan MK, et al. Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model. Am J Obstet Gynecol . 2011;205(3):249.e1–8. doi: 10.1016/j.ajog.2011.06.024

[84] Santillan D.A., Rai K.K., Santillan M.K., et al. Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model // Am J Obstet Gynecol. 2011. Vol. 205, N 3. P. 249.e1–8. doi: 10.1016/j.ajog.2011.06.024

[85] Hajam IA, Dar PA, Shahnawaz I, et al. Bacterial flagellin – a potent immunomodulatory agent. Exp Mol Med. 2017;49(9):e373. doi: 10.1038/emm.2017.172

[86] Hajam I.A., Dar P.A., Shahnawaz I., et al. Bacterial flagellin – a potent immunomodulatory agent // Exp Mol Med. 2017. Vol. 49, N 9. P. e373. doi: 10.1038/emm.2017.172

[87] Scheiblhofer S, Laimer J, Machado Y, et al. Influence of protein fold stability on immunogenicity and its implications for vaccine design. Expert Rev Vaccines . 2017;16(5):479–489. doi: 10.1080/14760584.2017.1306441

[88] Scheiblhofer S., Laimer J., Machado Y., et al. Influence of protein fold stability on immunogenicity and its implications for vaccine design // Expert Rev Vaccines. 2017. Vol. 16, N 5. P. 479–489. doi: 10.1080/14760584.2017.1306441

[89] Toellner KM, Luther SA, Sze DM, et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med. 1998;187(8):1193–1204. doi: 10.1084/jem.187.8.1193

[90] Toellner K.M., Luther S.A., Sze D.M., et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching // J Exp Med. 1998. Vol. 187, N 8. P. 1193–1204. doi: 10.1084/jem.187.8.1193

[91] Urban JF Jr, Noben-Trauth N, Donaldson DD, et al. IL-13, IL-4Ralpha , and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis . Immunity. 1998;8(2):255–264. doi: 10.1016/s1074-7613(00)80477-x

[92] Urban J.F. Jr., Noben-Trauth N., Donaldson D.D., et al. IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis // Immunity. 1998. Vol. 8, N 2. P. 255–264. doi: 10.1016/s1074-7613(00)80477-x

[93] Cunningham AF, Khan M, Ball J, et al. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol. 2004;34(11):2986–2995. doi: 10.1002/eji.200425403

[94] Cunningham A.F., Khan M., Ball J., et al. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1 // Eur J Immunol. 2004. Vol. 34, N 11. P. 2986–2995. doi: 10.1002/eji.200425403

[95] Bretscher PA. On the mechanism determining the TH1/TH2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases. Scand J Immunol. 2014;79(6):361–376. doi: 10.1111/sji.12175

[96] Bretscher P.A. On the mechanism determining the TH1/TH2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases // Scand J Immunol. 2014. Vol. 79, N 6. P. 361–376. doi: 10.1111/sji.12175

[97] Wang G, de Jong RN, van den Bremer ET, et al. Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen. Mol Cell . 2016;63:135–145. doi: 10.1016/j.molcel.2016.05.016

[98] Wang G., de Jong R.N., van den Bremer E.T., et al. Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen // Mol Cell. 2016. Vol. 63. P. 135–145. doi: 10.1016/j.molcel.2016.05.016

[99] Cheng Q, Carlson B, Pillai S, et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun. 2001;69(4):2302–2308. doi: 10.1128/IAI.69.4.2302-2308.2001

[100] Cheng Q., Carlson B., Pillai S., et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci // Infect Immun. 2001. Vol. 69, N 4. P. 2302–2308. doi: 10.1128/IAI.69.4.2302-2308.2001

[101] Arlian BM, Tinker JK. Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice. Clin Vaccine Immunol. 2011;18(9):1543–1551. doi: 10.1128/CVI.05146-11

[102] Arlian B.M., Tinker J.K. Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice // Clin Vaccine Immunol. 2011. Vol. 18, N 9. P. 1543–1551. doi: 10.1128/CVI.05146-11

[103] Zhang L. Multi-epitope vaccines: a promising strategy against tumors and viral infections. Cell Mol Immunol. 2018;15(2):182–184 . doi: 10.1038/cmi.2017.92

[104] Zhang L. Multi-epitope vaccines: a promising strategy against tumors and viral infections // Cell Mol Immunol. 2018. Vol. 15, N 2. P. 182–184. doi: 10.1038/cmi.2017.92

[105] Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32(18):2100–2108. doi: 10.1016/j.vaccine.2014.02.004

[106] Ma C., Li Y., Wang L., et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines // Vaccine. 2014. Vol. 32, N 18. P. 2100–2108 . doi: 10.1016/j.vaccine.2014.02.004

[107] Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science. 2005;310:1510–1512. doi: 10.1126/science.1118948

[108] Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding // Science. 2005. Vol. 310. P. 1510–1512. doi: 10.1126/science.1118948

[109] Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47. doi: 10.1038/nri2206

[110] Nimmerjahn F., Ravetch J.V. Fc gamma receptors as regulators of immune responses // Nat Rev Immunol. 2008. Vol. 8. P. 34–47. doi: 10.1038/nri2206

[111] Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi: 10.3389/fimmu.2014.00520

[112] Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions // Front Immunol. 2014. Vol. 5. P. 520. doi: 10.3389/fimmu.2014.00520

RIGHTS & PERMISSIONS

Eco-Vector